| Literature DB >> 35012187 |
Julia Sánchez-Bodón1, Jon Andrade Del Olmo1,2, Jose María Alonso2, Isabel Moreno-Benítez1, José Luis Vilas-Vilela1,3, Leyre Pérez-Álvarez1,3.
Abstract
Titanium (Ti) and its alloys have been demonstrated over the last decades to play an important role as inert materials in the field of orthopedic and dental implants. Nevertheless, with the widespread use of Ti, implant-associated rejection issues have arisen. To overcome these problems, antibacterial properties, fast and adequate osseointegration and long-term stability are essential features. Indeed, surface modification is currently presented as a versatile strategy for developing Ti coatings with all these challenging requirements and achieve a successful performance of the implant. Numerous approaches have been investigated to obtain stable and well-organized Ti coatings that promote the tailoring of surface chemical functionalization regardless of the geometry and shape of the implant. However, among all the approaches available in the literature to functionalize the Ti surface, a promising strategy is the combination of surface pre-activation treatments typically followed by the development of intermediate anchoring layers (self-assembled monolayers, SAMs) that serve as the supporting linkage of a final active layer. Therefore, this paper aims to review the latest approaches in the biomedical area to obtain bioactive coatings onto Ti surfaces with a special focus on (i) the most employed methods for Ti surface hydroxylation, (ii) SAMs-mediated active coatings development, and (iii) the latest advances in active agent immobilization and polymeric coatings for controlled release on Ti surfaces.Entities:
Keywords: active layer; bioactive coatings; controlled release; immobilization; pre-activation treatments; self-assembled monolayer (SAM); surface modification; titanium
Year: 2021 PMID: 35012187 PMCID: PMC8747097 DOI: 10.3390/polym14010165
Source DB: PubMed Journal: Polymers (Basel) ISSN: 2073-4360 Impact factor: 4.329
Figure 1General schematic representation of the layers and chemical components of Ti surfaces before and after cleaning and activation treatments. Contact angle and XPS spectrum of O1s photopeak narrow-scan with O2−, OH−, and H2O components are also shown as common characterizations.
Figure 2Different physical and chemical treatments for activation of Ti surface with their advantages (green) and disadvantages (red).
Figure 3Graphic comparison of the surface hydroxylation and oxidation (TiOH/oxide ratio) effectiveness for each Ti surface activation method.
Figure 4Schematic representation of silanes covalently immobilized onto Ti surfaces: (A) TESPSA immobilization onto Ti dental implant, (B) APTES immobilization onto Ti6Al4V alloy and (C) APTES and TEOS immobilization onto Ti6Al4V and their further functionalization.
Figure 5Schematic representation of different alkyl phosphonic acid immobilization onto Ti or its alloys: (A) functionalization strategy of aminophosphonates with different leghts onto Ti implant, (B) NDPA, HDPA, PUA and PHA immobilization scheme onto TiO2 implant, (C) Different phosphonate copolymers immobilization onto Ti6Al4V, (D) MDP, PTP and ETP phosphonic acids immobilization onto Ti disks.
Figure 6Schematic representation of GLK13K protein immobilization onto Ti surface.
Figure 7Schematic representation of different bioactive compound immobilization through silanization.
Figure 8Schematic representation polyNaSS immobilization via catechol strategy and click chemistry.
Figure 9Example of a hyaluronic acid hydrogel coating on Ti6Al4V surface for potential active agents delivery.
Hydrogel coatings for active agents release in biomedical area to create Ti active surfaces.
| Hydrogel Coating | Released Active Agent (s) | Biomedical Application | Reference |
|---|---|---|---|
| Polycarboxylic/amino functionalized hyaluronic acid | Vancomycin | Prevention of bacterial adhesion | [ |
| Hyaluronic acid | Vancomycin | Enhancement of osseointegration | [ |
| Recombinant human bone morphogenetic protein (rhBMG)-2 | Enhancement of peri-implant osteogenesis | [ | |
| Hyaluronic acid and polylactic acid | Vancomycin | Enhancement of antibacterial properties | [ |
| Vancomycin | Enhancement of antibacterial properties | [ | |
| Carboxymethyl chitosan | Silver nanoparticles | Improve antibacterial and bioactive properties | [ |
| Carboxymethyl chitosan and chitosan | Interleukin-4 (IL-4) and interferon-γ (IFN-γ) cytokines | Immunomodulation and anti-inflammatory properties | [ |
| Chitosan | Vancomycin | Bone regeneration | [ |
| Ibuprofen | Drug elution on conductive implants | [ | |
| Ibuprofen | Controlled drug delivery system | [ | |
| Interleukin-4 (IL-4) and heparin | Anti-inflammatory, anti-coagulation and anti-thrombus | [ | |
| Silver nanoparticles and naproxen | Enhancement of antibacterial and anti-inflammatory properties | [ | |
| Chitosan and silica xerogel | Fibroblast growth factor | Bioactivity enhancement | [ |
| Chitosan and gelatin | Ampicillin | Tissue engineering | [ |
| Gelatin | Antimicrobial peptide (AMP) and silicate nanoparticles | Prevention of infections and promotion of bone formation | [ |
| Gelatin and alginate | Vancomycin | Reduction of implant-related infection | [ |
| Alginate | Dopamine | Regulation of osteoclastic and osteogenic responses | [ |
| Alginate and 4-vynilphenylboronic acid | Vascular endothelial growth factor (VEGF) | Local drug delivery system | [ |
| Starch | Vancomycin | Prevention of bone infections | [ |
| Polyvinyl alcohol (PVA) and phospholipid polymer (PMBV) | Paclitaxel | Anticancer therapy | [ |
| poly(2-hydroxyethyl methacrylate) | Ciprofloxacin | Prevent implant associated infections | [ |
| poly(ethylene–glycol diacrylate) and acrylic acid | Silver nanoparticles | Enhancement of antibacterial properties | [ |
Figure 10General schematic representation of LbL assembly by spray-coating method of positively- and negatively-charged polymers onto Ti6Al4V surface with loaded active agents.
Figure 11Example of a release-based multilayer coating on Ti surface with cumulative sustained release profile of active agents after 140 h, and the release mechanism from multilayer systems through drug diffusion and multilayer degradation processes.
Multilayer coatings for active agents release in biomedical area to create Ti active surfaces.
| Multilayer Coating | Released Active Agent (s) | Biomedical Application | Reference |
|---|---|---|---|
| Hyaluronic acid and collagen | Enoxacin | Improvement of osteogenesis and osseointegration | [ |
| Hyaluronic acid and chitosan | Icariin | Improvement of osteogenesis | [ |
| Silver nanoparticles | Prevention of implant associated infections | [ | |
| Antimicrobial peptide-collagen | Long-term sustained antimicrobial activity | [ | |
| microRNAs | Enhancement of osteogenic activity | [ | |
| Hyaluronic acid and polylysine | Parathyroid hormone-related protein (PTHrP) | Enhancement of local bone formation | [ |
| Chitosan and bioactive glass | Vancomycin | Prevent implant associated infections | [ |
| Chitosan and β-cyclodextrin | Gentamicin | Enhancement of antibacterial properties | [ |
| Calcitriol (VD3) | Promotion of osseointegration | [ | |
| Chitosan and gelatin | Icariin | Regulation of osteoblast bioactivity | [ |
| Silver nanoparticles | Enhancement of antibacterial properties | [ | |
| Chitosan and alginate | Minocycline | Enhancement of antibacterial properties | [ |
| Gentamycin | Improvement of bone osseointegration and reduction of bacterial infections | [ | |
| Interleukin-4 (IL-4) cytokine | Modulation of macrophage phenotype for tissue repair | [ | |
| Chitosan, alginate and bovine serum albumin (BSA) | Bone morphogenetic protein-2 (BMP-2) | Tissue engineering | [ |
| Dextran and gelatin | A-melanocyte-stimulating hormone (α-MSH) | Improvement of bone remolding | [ |
| Polyacrylic acid and poly-L-lysine | Tetracycline | Enhancement of antibacterial properties | [ |
| Polyacrylic acid, poly-L-lysine and β-cyclodextrin | Tetracycline | Enhancement of antibacterial properties | [ |
| Poly (methacrylic acid) and poly-L-histidine | Bone morphogenetic protein-2 (BMP-2) and fibroblast growth factor (FGF) | Increase of bone growth | [ |